These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 39150076)

  • 1. Medications for Opioid Use Disorder after Entering Residential Treatment: Evidence from Louisiana Medicaid.
    Li W; Eisenberg M; Song M; Kennedy-Hendricks A; Saloner B
    J Addict Med; 2024 Aug; ():. PubMed ID: 39150076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medications For Opioid Use Disorder Increased Among Louisiana Medicaid Enrollees During Policy Reforms, 2018-21.
    Sugarman OK; Li W; Saloner B
    Health Aff (Millwood); 2024 Jan; 43(1):46-54. PubMed ID: 38190602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient follow-up and use of medications for opioid use disorder after residential treatment among Medicaid enrollees in 10 states.
    ; Cole ES; Allen L; Austin A; Barnes A; Chang CH; Clark S; Crane D; Cunningham P; Fry CE; Gordon AJ; Hammerslag L; Idala D; Kennedy S; Kim JY; Krishnan S; Lanier P; Mahakalanda S; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Tang L; Zivin K; Donohue JM
    Drug Alcohol Depend; 2022 Dec; 241():109670. PubMed ID: 36332591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of medication treatment for opioid-use disorder and risk of overdose among Medicaid enrollees in 11 states: a retrospective cohort study.
    Burns M; Tang L; Chang CH; Kim JY; Ahrens K; Allen L; Cunningham P; Gordon AJ; Jarlenski MP; Lanier P; Mauk R; McDuffie MJ; Mohamoud S; Talbert J; Zivin K; Donohue J
    Addiction; 2022 Dec; 117(12):3079-3088. PubMed ID: 35652681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions.
    Thomas CP; Stewart MT; Ledingham E; Adams RS; Panas L; Reif S
    JAMA Netw Open; 2023 Mar; 6(3):e232052. PubMed ID: 36884250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US.
    Stahler GJ; Mennis J
    Drug Alcohol Depend; 2020 Jul; 212():108067. PubMed ID: 32445926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting.
    Morgan JR; Barocas JA; Murphy SM; Epstein RL; Stein MD; Schackman BR; Walley AY; Linas BP
    JAMA Netw Open; 2020 Dec; 3(12):e2029676. PubMed ID: 33320266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between mortality rates and medication and residential treatment after in-patient medically managed opioid withdrawal: a cohort analysis.
    Walley AY; Lodi S; Li Y; Bernson D; Babakhanlou-Chase H; Land T; Larochelle MR
    Addiction; 2020 Aug; 115(8):1496-1508. PubMed ID: 32096908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care.
    Abraham AJ; Andrews CM; Harris SJ; Westlake MM; Grogan CM
    JAMA Health Forum; 2022 Nov; 3(11):e224001. PubMed ID: 36331441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
    Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
    J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
    Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
    JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding access to medication treatment for opioid use disorders: Findings from the Washington State hub and spoke effort.
    Stewart MT; Daily SM; Thomas CP; Panas L; Ritter G; Reif S
    Drug Alcohol Depend; 2024 Mar; 256():111125. PubMed ID: 38368666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic.
    Perry A; Wheeler-Martin K; Hasin DS; Terlizzi K; Mannes ZL; Jent V; Townsend TN; Pamplin JR; Crystal S; Martins SS; Cerdá M; Krawczyk N
    Drug Alcohol Depend; 2023 Dec; 253():111023. PubMed ID: 37984034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
    Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
    J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends and age-related disparities in opioid use disorder treatment admissions for adolescents and young adults.
    Welsh JW; Dennis ML; Funk R; Mataczynski MJ; Godley MD
    J Subst Abuse Treat; 2022 Jan; 132():108584. PubMed ID: 34391589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder.
    Nataraj N; Rikard SM; Zhang K; Jiang X; Guy GP; Rice K; Mattson CL; Gladden RM; Mustaquim DM; Illg ZN; Seth P; Noonan RK; Losby JL
    JAMA Netw Open; 2024 Apr; 7(4):e244617. PubMed ID: 38568691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study.
    Miller WA; Gordon AJ; Clothier BA; Ackland PE; Bounthavong M; Garcia C; Kenny ME; Noorbaloochi S; Hagedorn HJ
    Implement Res Pract; 2023; 4():26334895231199463. PubMed ID: 37790176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.